ORIC Pharmaceuticals Stock (NASDAQ: ORIC)

ORIC Pharmaceuticals

ORIC PHARMACEUTICALS INC

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Wall Street Bulls

News

Intraday Update

Markets

Movers

Trading Ideas

ACMR

APLD

HEES

HOOD

KULR

ORIC

QBTS

QUBT

RGTI

WULF

XPEV

H&amp;E Equipment Services, ACM Research, Robinhood And Other Big Stocks Moving Higher On Tuesday

PriceSmart

Pre-Market Outlook

PSMT

ROKU

URGN

VINP

PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

BAYRY


ORIC Pharmaceuticals (NASDAQ:ORIC) is a small-cap pharma stock. It aims to make a difference with its potentially &#34;best-in-class&#34; treatments. The company’s shares have not had a great year, returning -4% in 2024.

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals Inc

Orica Ltd

Health Care

Press Releases

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Small Cap

Opinion

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

General

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

ADPT

ELEV

ONCY

TSX:ONC

Abivax

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Celcuity

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

Erasca

Heron Therapeutics

Immatics

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Oruka Therapeutics

Precigen

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Relay Therapeutics

Sage Therapeutics

Stoke Therapeutics

Tourmaline Bio

Tyra Biosciences

Upstream Bio

Verve Therapeutics

JP Morgan

HC Wainwright & Co.

Wells Fargo

Jones Trading

Wedbush

Comments

ORIC Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga